Furthermore, SGLT2 inhibitors can hinder the formation of reactive oxygen species in experimental diabetic kidney disease 19, and the antioxidant characteristic of SGLT2 inhibitors could alter the development of several diseases including liver diseases, neural defects, and neoplasm 24. Here, SLC5A2 is linked to liver disorder.